DXCM vs SOLV: stock comparison and AI forecast
Dexcom Inc (DXCM) and Solventum Corp (SOLV) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DXCM Dexcom Inc
- Price
- $79.41 +30.4% · 6M
- Market Cap
- $29.62B
- P/E Ratio
- 28.9x
- Size
- large-cap
- AI Forecast
SOLV Solventum Corp
- Price
- $87.18 +21.7% · 6M
- Market Cap
- $14.84B
- P/E Ratio
- 80.7x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- DXCM is 2.0 times larger than SOLV by market capitalization ($29.62B against $14.84B).
- DXCM trades at 28.9 times trailing earnings, SOLV at 80.7 times.
- Over the last six months DXCM returned +30.4% and SOLV +21.7%.
- DXCM turns 19.4% of its revenue into net income, against 1.9% for SOLV.
- SOLV carries 1.95 times debt per unit of equity, against 1.46 times for DXCM.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DXCM | SOLV |
|---|---|---|
| Market Cap | $29.62B | $14.84B |
| P/E Ratio | 28.88x | 80.72x |
| P/B Ratio | 11.68x | 3.09x |
| EPS | $2.75 | $1.08 |
| Book Value/Share | $6.80 | $28.23 |
| Revenue/Share | $13.69 | $47.95 |
| FCF/Share | $2.94 | $0.00 |
Profitability & Margins
| Metric | DXCM | SOLV |
|---|---|---|
| ROE | 39.1% | 3.2% |
| ROA | 15.9% | 1.1% |
| ROIC | 30.7% | 4.3% |
| Gross Margin | 63.4% | 54.8% |
| Operating Margin | 24.0% | 5.6% |
| Net Margin | 19.4% | 1.9% |
| EBT Margin | 24.7% | 2.1% |
| Tax Rate | 21.5% | 8.2% |
Financial Health
| Metric | DXCM | SOLV |
|---|---|---|
| Current Ratio | 1.74x | 1.03x |
| Quick Ratio | 1.40x | 0.72x |
| D/E Ratio | 1.46x | 1.95x |
| Financial Leverage | 2.46x | 2.95x |
| Interest Coverage | 155.8x | 0.3x |
| Working Capital | $1.66B | $117M |
Cash Flow
| Metric | DXCM | SOLV |
|---|---|---|
| Operating Cash Flow | $1.41B | $310M |
| Free Cash Flow | $1.10B | $0.00M |
| Capital Spending | -$316M | -$310M |
| OCF Growth YoY | -2.3% | -37.1% |
| FCF Growth YoY | 3.4% | -100.0% |
| FCF/Sales | 21.5% | 0.0% |
| CapEx/Sales | 6.2% | 3.8% |
Operational Efficiency
| Metric | DXCM | SOLV |
|---|---|---|
| Asset Turnover | 0.82x | 0.58x |
| Receivables Turnover | 4.3x | 6.0x |
| Inventory Turnover | 2.4x | 3.4x |
| Fixed Assets Turnover | 3.3x | 5.9x |
| Days Sales Outstanding | 85 days | 61 days |
| Days Inventory | 151 days | 109 days |
| Payables Period | 404 days | 80 days |
| Cash Conversion Cycle | -168 days | 90 days |
Income Statement
| Metric | DXCM | SOLV |
|---|---|---|
| Total Revenue | $5.10B | $8.16B |
| Operating Income | $1.22B | $455M |
| Net Income | $991M | $156M |
| R&D Expense | $608M | $722M |
| SG&A Expense | $1.41B | $3.33B |
| Cost of Goods Sold | $1.87B | $3.69B |
Dividend & Shareholder Information
| Metric | DXCM | SOLV |
|---|---|---|
| Shares Outstanding | 373M | 170M |
| Net Income Growth | 37.5% | -89.8% |
| EPS Growth | 54.5% | -86.3% |
DXCM vs SOLV: stock comparison and AI forecast
Which is bigger, DXCM or SOLV?
DXCM is 2.0 times larger than SOLV by market capitalization ($29.62B against $14.84B).
Which is cheaper on earnings, DXCM or SOLV?
DXCM trades at 28.9 times trailing earnings, SOLV at 80.7 times.
Which stock performed better over the last six months, DXCM or SOLV?
Over the last six months DXCM returned +30.4% and SOLV +21.7%.
Which one does Intratio's AI model rank higher, DXCM or SOLV?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.